MarginsXMarginsX
Home › Markets › Health Care › MSLE

Satellos Bioscience Inc. (MSLE)

MSLE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$6.47
-2.34% on the day
Market cap
$137.3M
Micro cap
Revenue
Foreign filer: no machine-readable annual figure in SEC data
Net income
Foreign filer: no machine-readable annual figure in SEC data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerMSLE on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryCanada
IPO yearNot reported by the screener
SEC CIK0001421642
SEC industry codePharmaceutical Preparations
Incorporated inCanada
Canadian listingTSX: MSCL

Financials

Foreign filer: no machine-readable annual figure in SEC data.

Warning signs

Cash runway
5.0 months
$9.8M cash at December 31, 2025
Share count, 1 year
See the dilution note
Going-concern doubt
No
40-F filed March 27, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.40-F 2026-03-27
Cash and burn$9.8M cash; operating cash flow -$5.9M a quarter.Report 2025-12-31
Shares outstanding15,458,903 (2025-12-31). the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 years1; latest 1-for-12 on 2026-01-30Source 2026-01-30
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Toronto, CanadaPCAOB Form AP 2026-04-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
Not filed-$24.9M-$23.6M$9.8MNo debt tagsNeeds four quarters40-F 2026-03-27
FY 2024
2024-12-31
Not filed-$20.6M-$18.3M$40.1MNo debt tagsNeeds four quarters40-F 2026-03-27

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest annual report40-F2026-03-27
Latest quarterly / interim
FORM 6-K
6-K2026-11-12

Source: SEC EDGAR submissions feed, 56 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-7.9%
1 month-5.9%
3 months-32.5%
Year to date+12.7%
1 year+10.4%
From 52-week high-49.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
MGNXMacroGenics Inc.$2.17-1.36%$138.7M
RNAAtrium Therapeutics Inc.$6.43-14.38%$138.7M
MENSJyong Biotech Ltd.$1.77+0.57%$134.6M
SIONSionna Therapeutics Inc.$3.12-6.31%$141.1M
NTHINeOnc Technologies Holdings Inc.$4.54-7.54%$131.0M
CNTNCanton Strategic Holdings Inc.$1.64-4.09%$130.7M
VRXAVeraxa Biotech AG$1.04-5.86%$147.8M
ABEOAbeona Therapeutics Inc.$2.60+7.44%$148.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier